Go to deals
Private Equity | Healthcare

DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm

The owner of DIAGOMICS has sold the company to ZytoMax GmbH.

Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.

Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.

Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.

Parties
“DIAGOMICS has reached a strategic turning point given its rapid and exponential growth. To strengthen our market position and continue to offer innovative and quality products, DIAGOMICS is joining the ZytoMax group. Our shared values, such as scientific expertise and customer proximity, contributed to this choice.”

Gwénola Tanneau

Founder and CEO, DIAGOMICS

Talk to the deal team

Xavier Auvergnat

Partner
Toulouse, France
Oaklins France

Théo Cavalière

Analyst
Toulouse, France
Oaklins France

Related deals

Bayer AG has entered into a takeover agreement with Cara Care
Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more
Mark Climate Technology has acquired Heber GmbH
Private Equity | Industrial Machinery & Components | Other Industries

Mark Climate Technology has acquired Heber GmbH

Heber GmbH has been acquired by Mark Climate Technology, a specialist in climate control systems and a portfolio company of Bolster Investment Partners. This partnership strengthens the positions of both companies in the global market for innovative and sustainable climate solutions, as well as creating unique synergies. Mark Climate's expertise in standardized, scalable solutions is enhanced by Heber's emphasis on customer-specific customization.

Learn more
Grupo Veta 2017 S.L. has been acquired by MSA Mizar
Private Equity | Business Support Services | Financial Services | TMT

Grupo Veta 2017 S.L. has been acquired by MSA Mizar

The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.

Learn more